




The 3C Study

Campath, Calcineurin inhibitor reduction and Chronic allograft nephropathy



Participant name
Participant address

The 3C Study
Clinical Trial Service Unit (CTSU)
Richard Doll Building
University of Oxford
Old Road Campus
Headington
Oxford
OX3 7LF

Participant ID:

Date

Office telephone: 01865 743528
Office fax: 01865 743981
Freefone: 0800 585323

[E-mail: ccc@ctsu.ox.ac.uk](mailto:ccc@ctsu.ox.ac.uk)

Dear Participant,

Thank you very much for agreeing to participate in the 3C Study. We are very grateful for your help and hope that this study will provide invaluable information for doctors caring for kidney transplant recipients in the near future. Please find enclosed your annual questionnaire which we would be very grateful if you could complete and return to us in the enclosed Freepost envelope. We would be very grateful if you could do so – even if you think nothing has changed with your health recently – as this will provide invaluable information for the study.

As you may recall, we also plan to collect information about your health from various NHS registries which routinely collect such data from hospitals. The Health and Social Care Information Centre (HSCIC) hold such information on all patients in the NHS and we sought your permission at the start of the trial to request information about you from them. This will require us to share (securely) your name, date of birth and NHS number with the HSCIC so they know who to send us data on. The data they provide to us will include information (e.g., date and reason) for any hospital attendances or admissions you have and information if you are diagnosed with cancer, or if you die information provided by the Office for National Statistics on your date and cause of death. We may also collect data about your transplant from other NHS registries such as the UK Transplant Registry and UK Renal Registry. Any information we receive will only be used for trial purposes and we will never share your confidential data with anyone else. If you have any questions about this or no longer wish to let us use such information, please contact the trial team on the numbers above.

Thank you again for agreeing to participate in this important study. Please do not hesitate to contact us if you have any questions about the content of this letter, the questionnaire or the study in general.

With kind regards.

Yours sincerely

Professor Peter Friend
Chief Investigator, the 3C Study